Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georges Maestroni

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Nature Immunology|July 30, 2004
Immunology needs the mindGeorges Maestroni
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|September 10, 2020
Exogenous melatonin as potential adjuvant in anti-SarsCov2 vaccinesGeorges Maestroni
Cytokine|June 21, 2011
β2-Adrenergic agonists bias TLR-2 and NOD2 activated dendritic cells towards inducing an IL-17 immune responseMichela Manni, Richard D Granstein, Georges Maestroni
Neuro Endocrinology Letters|August 27, 2002
Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid systemPaolo Lissoni, Fabio Malugani, Ola Malysheva, et al.
Neuro Endocrinology Letters|July 17, 2001
Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alonePaolo Lissoni, Franco Rovelli, Andrea Frassineti, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Nature Immunology|July 30, 2004
Immunology needs the mindGeorges Maestroni
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|September 10, 2020
Exogenous melatonin as potential adjuvant in anti-SarsCov2 vaccinesGeorges Maestroni
Cytokine|June 21, 2011
β2-Adrenergic agonists bias TLR-2 and NOD2 activated dendritic cells towards inducing an IL-17 immune responseMichela Manni, Richard D Granstein, Georges Maestroni
Neuro Endocrinology Letters|August 27, 2002
Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid systemPaolo Lissoni, Fabio Malugani, Ola Malysheva, et al.
Neuro Endocrinology Letters|July 17, 2001
Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alonePaolo Lissoni, Franco Rovelli, Andrea Frassineti, et al.
Pageof 1